Valneva SE Sponsored ADR (NASDAQ:VALN) Given Consensus Recommendation of "Hold" by Analysts

Key Points

• Valneva has a consensus “Hold” rating from four analysts, split between two buy and two sell recommendations. The average 12-month price target is $9.30, with TD Cowen recently initiating coverage at “Buy” and a $12 target.
• The company missed quarterly expectations, reporting a loss of $0.40 per share versus the $0.19 consensus estimate and revenue of $39.37 million versus $44.17 million expected. Analysts anticipate a full-year loss of $1.27 per share.
• Valneva shares opened at $6.75, while institutional investors and hedge funds own 11.39% of the stock. The company continues to operate as a specialty vaccine developer and markets products including IXIARO/JESPECT and DUKORAL.

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) have received an average rating of "Hold" from the four ratings firms that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $9.30.

A number of analysts recently issued reports on the stock. TD Cowen began coverage on shares of Valneva in a report on Tuesday, August 11th. They set a "buy" rating and a $12.00 price target on the stock. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Valneva in a report on Thursday, June 18th. Finally, Wall Street Zen upgraded shares of Valneva from a "strong sell" rating to a "sell" rating in a research report on Monday, June 1st.

Hedge Funds Weigh In On Valneva

A number of large investors have recently bought and sold shares of the business. XTX Topco Ltd purchased a new position in Valneva during the fourth quarter worth approximately $94,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Valneva in the fourth quarter valued at approximately $44,000. JPMorgan Chase & Co. acquired a new position in shares of Valneva during the 3rd quarter worth approximately $124,000. Finally, Marex Group plc acquired a new position in shares of Valneva during the 2nd quarter worth approximately $64,000. Institutional investors and hedge funds own 11.39% of the company's stock.

Valneva Stock Down 3.0%

Valneva stock opened at $6.75 on Tuesday. The business's 50-day simple moving average is $5.43 and its two-hundred day simple moving average is $6.80. The company has a debt-to-equity ratio of 2.04, a quick ratio of 1.69 and a current ratio of 2.16. The company has a market cap of $640.51 million, a PE ratio of -3.20 and a beta of 1.77. Valneva has a fifty-two week low of $4.75 and a fifty-two week high of $12.23.

Valneva (NASDAQ:VALN - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.21). The company had revenue of $39.37 million during the quarter, compared to analyst estimates of $44.17 million. Valneva had a negative net margin of 110.33% and a negative return on equity of 153.20%. Equities analysts anticipate that Valneva will post -1.27 EPS for the current year.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva's research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.